Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Birth Control Pills Series: Are the Current FDA Label Warnings Enough?

December 19, 2016 By Law Offices of Thomas J. Lamb, P.A.


In the previous article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, I discussed the devastating side effects that can result from using these DRSP-containing birth control pills.

For my final article in this series, I will discuss the current drug label warnings for these drugs, and contemplate whether these warnings are sufficient.

As discussed in my previous article, studies conducted in 2009, as well as the FDA findings in 2012 led to a label change for the DRSP-containing birth control pills. The 2012 drug label warned that the risk of venous thromboembolism (VTE) is greater among those who use DRSP-containing birth control pills such as Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz.

In spite of this new warning, there have been “more than 10,800 adverse events reported to [the] FDA by health professionals and manufacturers” concerning DRSP birth control pills, according to the article, “Lawsuits Follow PMDD Diagnosis: Lowering the Bar.”  Furthermore, 6,000 of those reports involved hospitalizations, and 200 reports involved deaths.

Unfortunately, tragic stories of women using these DRSP birth control pills are far from scarce.  One woman’s story is discussed in the aforementioned article, and involves twenty-nine year-old, Oconomowoc native, Cayla Hibbard.  Hibbard took Yasmin as a means of birth control and alleviating severe menstrual symptoms.  When she started taking Yasmin, Hibbard lived an active lifestyle and was going to school for massage therapy.

However, one day, she was hospitalized after experiencing difficulty breathing while climbing stairs.  She was diagnosed with a pulmonary embolism, which is a potentially fatal blood clot in the lungs.  As a result, Hibbard had to use blood thinning medications for approximately six months after her diagnosis.

Hibbard filed a lawsuit against Bayer claiming that they “knew or should have known that Yasmin was being used to treat menstrual symptoms, even though it is not approved for that.  The lawsuit also argued the company fraudulently concealed the safety risks of the drug in order to induce doctors to prescribe it.”

There are thousands of women like Hibbard who have also experienced devastating side effects after using these DRSP birth control pills.  While Hibbard survived this terrible episode, other women who used these birth control pills have not been so fortunate.  Since the late 2000s, more than 12,000 women in America have filed lawsuits against Bayer for injuries or deaths resulting from use of Yaz and Yasmin, alone.  In addition, many more lawsuits have been filed against Bayer by women who used Safyral, Beyaz, Ocella, and Gianvi for similar devastating side effects.

Given that such a large number of women are still suffering from life-threatening side effects resulting from DRSP birth control pills, it may be time for the FDA to strengthen their warnings.  It seems as though the warnings added to the drug labels for the DRSP birth control pills in 2012 are not sufficient.  How many more women need to suffer before the FDA releases a new label change, bearing stronger warnings?

Do you have a story similar to Cayla Hibbard, and the thousands of other women who have suffered due to Yaz, Yasmin, Ocella, Gianvi, Safyral, or Beyaz?  Tell us about it by leaving a comment, or by completing a free case evaluation.

We will continue to monitor the medical literature concerning Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, and hope to see a new label change in the near future for these birth control pills.


Series Overview:

Article 1 – Creating a Clinical Disorder for Profit
Article 2 – The Devastating Side Effects
Article 3 – Are the Current FDA Label Warnings Enough?


Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.


Drug Injury Watch
: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: adverse drug effects, Bayer, Beyaz, birth control pills, birth control side effects, blood clots, drospirenone, DRSP, DVT, FDA, FDA drug label warnings, Gianvi, Ocella, PE, PMDD, PMDD treatments, Safyral, severe PMS treatments, venous thromboembolism, VTE, Yasmin, Yaz

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.